AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8739854 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer subjects
Number of subjects: 975
Study 8739854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients with upper gastrointestinal tract tumors
Number of subjects: 975
Study 8739854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients subdivided according to the extension of the tumor (TNM system)
Number of subjects: 975
Study 1764147 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour, in-hospital telephone line for advice by postpartum nurses
Number of subjects: 260
Study 1764147 — intervention group
Group type: COMPARATOR
Intervention: Regular ward telephones (control group)
Number of subjects: 260
Study 7048172 — intervention group
Group type: EXPERIMENTAL
Intervention: chemo + radiotherapy + BCG therapy
Number of subjects: 16
Study 7048172 — intervention group
Group type: COMPARATOR
Intervention: chemo + radiotherapy
Number of subjects: 16
Study 7048172 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG therapy
Number of subjects: 16
Study 31596491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target < 120 mm Hg)
Number of subjects: 9361
Study 31596491 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target < 140 mm Hg)
Number of subjects: 9361
Study 28546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1mg.kg‐1
Number of subjects: 90
Study 28546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1mcg.kg‐1
Number of subjects: 90
Study 28546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5mcg.kg‐1
Number of subjects: 90
Study 26808841 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squats at 140° knee angle
Number of subjects: 14
Study 26808841 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squats at 90° knee angle
Number of subjects: 14
Study 26808841 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 14
Study 26808841 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squats at 90° for high jumpers
Number of subjects: 14
Study 26808841 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squats at 140° for high jumpers
Number of subjects: 14
Study 24637999 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (C2 to C22)
Number of subjects: 1759
Study 24637999 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (C2 to C6) plus placebo (C7 to C22)
Number of subjects: 1759
Study 24637999 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus placebo (C2 to C22)
Number of subjects: 1759
Study 22289280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training plus usual care (UC)
Number of subjects: 86
Study 20919771 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk‐Taking and Self‐Harm Inventory for Adolescents (RTSHIA)
Number of subjects: 722
Study 20919771 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measures of adolescent psychopathology
Number of subjects: 722
Study 17627173 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg piroxicam FDDF sublingual tablets
Number of subjects: 80
Study 17627173 — intervention group
Group type: COMPARATOR
Intervention: IM injection of 40 mg piroxicam
Number of subjects: 80
Study 15850682 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap group (12 children)
Number of subjects: 24
Study 15850682 — intervention group
Group type: COMPARATOR
Intervention: Vertical group (7 children)
Number of subjects: 24
Study 15850682 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 24
Study 12039932 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation Planning
Number of subjects: 94
Study 12039932 — intervention group
Group type: COMPARATOR
Intervention: Productive Listening (Control)
Number of subjects: 94
Study 9594288 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG (200 IU intramuscularly at 3, 2, and 1 month before delivery)
Number of subjects: 204
Study 9594288 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 204
Study 9594288 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG
Number of subjects: 204
Study 9594288 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 204
Study 7959520 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20‐40 mg, n = 54)
Number of subjects: 106
Study 7959520 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20‐60 mg, n = 52)
Number of subjects: 106
Study 3298327 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate
Number of subjects: 0
Study 3298327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30782722 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Areas In Diabetes (PAID) scale intervention in clinical diabetes consultations
Number of subjects: 0
Study 30782722 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical diabetes consultations without the PAID scale
Number of subjects: 0
Study 29351604 — intervention group
Group type: EXPERIMENTAL
Intervention: Results-based financing (RBF)
Number of subjects: 0
Study 27483065 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (titrated up to 0.06 U/min) and hydrocortisone (n=101)
Number of subjects: 409
Study 27483065 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and placebo (n=104)
Number of subjects: 409
Study 27483065 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine and hydrocortisone (n=101)
Number of subjects: 409
Study 27483065 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine and placebo (n=103)
Number of subjects: 409
Study 27483065 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 409
Study 27483065 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 409
Study 24501378 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month moderate-intensity aerobic exercise intervention (45 minutes/day, 5 days/week)
Number of subjects: 173
Study 24501378 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month moderate-intensity aerobic exercise intervention
Number of subjects: 173
Study 24501378 — intervention group
Group type: COMPARATOR
Intervention: Stretching control
Number of subjects: 173
Study 22220766 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg followed by 250 mg 24 hours later
Number of subjects: 9
Study 22220766 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy sextants)
Number of subjects: 9
Study 19170197 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (AP)
Number of subjects: 6
Study 19170197 — intervention group
Group type: COMPARATOR
Intervention: Tetrabenazine (TBZ)
Number of subjects: 6
Study 17141356 — intervention group
Group type: EXPERIMENTAL
Intervention: OSWALD under informative dropout (ID)
Number of subjects: 0
Study 17141356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap procedure supplementing OSWALD
Number of subjects: 0
Study 17141356 — intervention group
Group type: COMPARATOR
Intervention: OSWALD under completely random dropout (CRD)
Number of subjects: 0
Study 17141356 — intervention group
Group type: COMPARATOR
Intervention: OSWALD under random dropout (RD)
Number of subjects: 0
Study 15040643 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 600 mg once/day
Number of subjects: 32
Study 15040643 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine 300 mg twice/day
Number of subjects: 32
Study 11139305 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape information
Number of subjects: 0
Study 11139305 — intervention group
Group type: COMPARATOR
Intervention: Written information
Number of subjects: 0
Study 9729573 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg/kg)
Number of subjects: 9
Study 8002329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of sublingual apomorphine
Number of subjects: 22
Study 8002329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3261951 — intervention group
Group type: EXPERIMENTAL
Intervention: Tightly fitting face mask
Number of subjects: 80
Study 3261951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen flow of 10 l/min
Number of subjects: 80
Study 3261951 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of preoxygenation (5 min)
Number of subjects: 80
Study 3261951 — intervention group
Group type: EXPERIMENTAL
Intervention: SaO2
Number of subjects: 80
Study 3261951 — intervention group
Group type: EXPERIMENTAL
Intervention: CaO2
Number of subjects: 80
Study 7802151 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (AE): alfentanil 30 micrograms/kg and etomidate 0.3 mg/kg
Number of subjects: 80
Study 7802151 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (AP): alfentanil 30 micrograms/kg and propofol 1.5 mg/kg
Number of subjects: 80
Study 7802151 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (SE): sufentanil 0.3 microgram/kg and etomidate 0.3 mg/kg
Number of subjects: 80
Study 7802151 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV (SP): sufentanil 0.3 microgram/kg and propofol 1.5 mg/kg
Number of subjects: 80
Study 42593 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of quazepam (Sch-16134)
Number of subjects: 0
Study 42593 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31071147 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing or being immersed in father-friendly prenatal care office cues (online videos or in-person visits)
Number of subjects: 0
Study 31071147 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 0
Study 28486629 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block with ropivacaine 0.15%, 1.5 ml kg ‐1 (High-Volume group)
Number of subjects: 80
Study 28486629 — intervention group
Group type: COMPARATOR
Intervention: Caudal block with ropivacaine 0.15%, 1.0 ml kg ‐1 (Low-Volume group)
Number of subjects: 80
Study 26419732 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic medication exposure
Number of subjects: 99
Study 23301757 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (PIP/TAZO) plus amikacin (AMK)
Number of subjects: 46
Study 23301757 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone-sulbactam (CS) plus amikacin (AMK)
Number of subjects: 46
Study 23301757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PIP/TAZO+AMK and CS+AMK)
Number of subjects: 46
Study 21160054 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied behaviour analysis by a specialist team plus standard treatment
Number of subjects: 0
Study 21160054 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (control)
Number of subjects: 0
Study 19359073 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (14 g/day)
Number of subjects: 44
Study 19359073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16754923 — intervention group
Group type: EXPERIMENTAL
Intervention: No additional diagnostic testing for PE (experimental intervention)
Number of subjects: 1126
Study 16754923 — intervention group
Group type: COMPARATOR
Intervention: Additional diagnostic testing (control intervention)
Number of subjects: 1126
Study 15167306 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 74
Study 15167306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11308049 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (Genotropin) at a dose of 0.2 IU/kg/day as daily s.c. injections for two years
Number of subjects: 26
Study 11308049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26
Study 9329513 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine plus didanosine
Number of subjects: 240
Study 9329513 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine plus zalcitabine
Number of subjects: 240
Study 9329513 — intervention group
Group type: COMPARATOR
Intervention: zidovudine only
Number of subjects: 240
Study 9329513 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine plus didanosine and zidovudine plus zalcitabine
Number of subjects: 240
Study 9329513 — intervention group
Group type: COMPARATOR
Intervention: zidovudine monotherapy
Number of subjects: 240
Study 9329513 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study 9329513 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-therapy groups
Number of subjects: 240
Study 7950213 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline extract of Euphorbia fisheriana (EF)
Number of subjects: 72
Study 7950213 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-blind treatment with EF
Number of subjects: 72
Study 7950213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3665359 — intervention group
Group type: EXPERIMENTAL
Intervention: LSL group (ipsilateral limb)
Number of subjects: 16
Study 3665359 — intervention group
Group type: COMPARATOR
Intervention: LOL group (contralateral limb)
Number of subjects: 16
Study 31838642 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation with rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol)
Number of subjects: 20
Study 31838642 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol)
Number of subjects: 20
Study 31229401 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox alone (30 mg/kg daily)
Number of subjects: 62
Study 31229401 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox and deferoxamine combination (30 mg/kg deferasirox daily plus SC 50 mg/kg deferoxamine for 5 days a week)
Number of subjects: 62
Study 31229401 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox and deferoxamine combination
Number of subjects: 62
Study 31229401 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox alone
Number of subjects: 62
Study 26890193 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A injection plus three ESWT sessions
Number of subjects: 10
Study 26890193 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A alone
Number of subjects: 10
Study 25405276 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 ml kg(‐1) h(‐1) during ERCP)
Number of subjects: 180
Study 25405276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (200 μg before ERCP)
Number of subjects: 180
Study 25405276 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasal placebo before ERCP and placebo during ERCP)
Number of subjects: 180
Study 25405276 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (R, F, P)
Number of subjects: 180
Study 23234763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg daily for 12 months)
Number of subjects: 3161
Study 23234763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 12 months)
Number of subjects: 3161
Study 21513687 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 162
Study 21513687 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 162
Study 18164689 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation times of 10, 50, 202, and 3000 ms (Experiment 1) plus unlimited presentation time (Experiment 2)
Number of subjects: 0
Study 16496099 — intervention group
Group type: EXPERIMENTAL
Intervention: Running suture technique with slowly absorbable monofilament suture material (PDS)
Number of subjects: 625
Study 16496099 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted technique with a braided, rapidly absorbable suture material (Vicryl)
Number of subjects: 625
Study 16496099 — intervention group
Group type: COMPARATOR
Intervention: Course organisation, content, and speaker evaluation during the surgical investigator meeting
Number of subjects: 625
Study 12091295 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (100 microg four times daily for 10 days via Aerochamber)
Number of subjects: 16
Study 12091295 — intervention group
Group type: COMPARATOR
Intervention: Systemic dexamethasone (0.5 mg/kg/day, reducing over nine days)
Number of subjects: 16
Study 9916960 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch retropubic urethropexy
Number of subjects: 35
Study 7743790 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment scales
Number of subjects: 0
Study 7743790 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklists for reporting RCTs
Number of subjects: 0
Study 2200237 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran muffins (4 per day)
Number of subjects: 16
Study 2200237 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 16
Study 6821438 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanol acetamidobenzoate
Number of subjects: 42
Study 6821438 — intervention group
Group type: COMPARATOR
Intervention: Orphenadrine
Number of subjects: 42
Study 6821438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 29764965 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control treatment aiming for SDAI remission (SDAI ≤ 3.3)
Number of subjects: 120
Study 29764965 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control treatment aiming for DAS28 remission (DAS28 < 2.6)
Number of subjects: 120
Study 29764965 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving sustained DAS28 remission
Number of subjects: 120
Study 29764965 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthoc analysis including all 110 patients with PWV
Number of subjects: 120
Study 27153835 — intervention group
Group type: EXPERIMENTAL
Intervention: Beardslee's Preventive Intervention Program (PIP), delivered in seven weekly sessions at the family home.
Number of subjects: 0
Study 27153835 — intervention group
Group type: COMPARATOR
Intervention: Control group following treatment as usual.
Number of subjects: 0
Study 25274500 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School and Heart Coherence Training (BS-HCT)
Number of subjects: 170
Study 25274500 — intervention group
Group type: COMPARATOR
Intervention: Back School (BS)
Number of subjects: 170
Study 22476829 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 240
Study 22476829 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (RYGB)
Number of subjects: 240
Study 20705782 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of lidocaine 2% 30 mL
Number of subjects: 100
Study 20705782 — intervention group
Group type: COMPARATOR
Intervention: Triple injection adjacent to each brachial plexus cord
Number of subjects: 100
Study 17631626 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive violence prevention program
Number of subjects: 1788
Study 17631626 — intervention group
Group type: EXPERIMENTAL
Intervention: School perceived as safe
Number of subjects: 1788
Study 17631626 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual risk factors (being male, childhood maltreatment, poor parental nurturing)
Number of subjects: 1788
Study 16255952 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of NPPV plus standard medical treatment (group B)
Number of subjects: 342
Study 16255952 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (group A)
Number of subjects: 342
Study 12135994 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher client fees for family planning and reproductive health services
Number of subjects: 15
Study 12135994 — intervention group
Group type: EXPERIMENTAL
Intervention: Price increases at tested levels
Number of subjects: 15
Study 10088941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaceprol (200 mg three times daily)
Number of subjects: 150
Study 10088941 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (25 mg three times daily)
Number of subjects: 150
Study 7562088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol treatment (30 g/d)
Number of subjects: 37
Study 7562088 — intervention group
Group type: COMPARATOR
Intervention: No alcohol treatment (energy replaced with carbohydrate)
Number of subjects: 37
Study 1705137 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg three times daily)
Number of subjects: 12
Study 1705137 — intervention group
Group type: EXPERIMENTAL
Intervention: Toloxatone (400-200-400 mg day-1)
Number of subjects: 12
Study 1705137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6450544 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen/nitrous oxide sedation (relative analgesia) with diazepam premedication 0.2 mg/kg
Number of subjects: 50
Study 6450544 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen/nitrous oxide sedation
Number of subjects: 50
Study 31134784 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy training for 8 weeks, 16 sessions, combined with conventional therapy 5 days a week
Number of subjects: 88
Study 31134784 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 88
Study 28422001 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cyclophosphamide (CYC) pulses combined with glucocorticoids
Number of subjects: 64
Study 28422001 — intervention group
Group type: COMPARATOR
Intervention: 6 cyclophosphamide (CYC) pulses combined with glucocorticoids
Number of subjects: 64
Study 26690638 — intervention group
Group type: EXPERIMENTAL
Intervention: Power of Food Scale (PFS) score higher at baseline
Number of subjects: 294
Study 26690638 — intervention group
Group type: EXPERIMENTAL
Intervention: Power of Food Scale (PFS) score
Number of subjects: 294
Study 23832170 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/DRSP (1 mg estradiol + 2 mg drospirenone)
Number of subjects: 160
Study 23832170 — intervention group
Group type: COMPARATOR
Intervention: E2/DG (1 mg estradiol + 5 mg dydrogesterone)
Number of subjects: 160
Study 23165381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline anhydrous, 200 to 800 mg/d for 2 to 12 months
Number of subjects: 10
Study 23165381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal theophylline methylpropyl paraben, 20 μg/d in each naris for 4 weeks
Number of subjects: 10